3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
13
Genitourinary
2
Thoracic
1
Sarcoma
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Primary Myelofibrosis
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
7
Carboplatin
5
Cisplatin
4
Drug Therapy
3
Taxes
2
Specimen Handling
2
SS1(dsFv)PE38
2
Polymerase Chain Reaction
2
Paclitaxel
2
Oxaliplatin
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Hyperthermic Intraperitoneal Chemotherapy
2
Gene Expression Profiling
2
Fluorouracil
2
Doxorubicin
2
Cyclophosphamide
2
130-nm albumin-bound paclitaxel
2
tremelimumab
1
tocilizumab
1
tinostamustine
1
sodium thiosulfate
1
selinexor
1
rucaparib
1
olaparib
1
motexafin lutetium
1
liposomal doxorubicin
1
fludarabine
1
eribulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
rucaparib
×
Thoracic
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts